Chimeric Therapeutics (ASX:CHM) Reports Positive ADVENT-AML Trial Results
Clinical Trial Progress
Chimeric Therapeutics (ASX:CHM) announced that in its ADVENT-AML Phase 1B clinical trial, two of three evaluable patients have achieved Complete Response with incomplete blood count recovery (CRi) in Acute Myeloid Leukemia (AML). The trial is designed to enroll 20 newly diagnosed AML patients who are not eligible for chemotherapy or allogeneic stem cell transplant.
Trial Details
ADVENT-AML is the first frontline AML trial to incorporate Chimeric’s CORE-NK cell therapy, combining it with standard AML treatment. The study, conducted at MD Anderson Cancer Centre under Principal Investigator Dr Abhishek Maiti, has completed enrollment for the dose-finding portion without safety concerns. The trial commenced in December 2024 and is anticipated to complete in December 2025.
Executive Comments
CEO Dr Rebecca McQualter stated, “This is great news for newly diagnosed AML patients who may benefit from our CORE-NK cells as their initial AML therapy. We are excited to be pioneers in the cell therapy sector, with the first frontline cell therapy study in AML led by MD Anderson Cancer Center.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
